Organon & Co | OGN - Ebitda


Organon & Co reported $371M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Celltrion KRW 25.72B 6.08B Jun/2026
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -46.46M 6.27M Mar/2026
Divis Laboratories Ltd INR 12.62B 3.28B Jun/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Kangmei Pharma CNY -12.72M 30.02M Mar/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Merck USD -1.54B 7.84B Mar/2026
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Novartis USD 5.41B 431M Mar/2026
Organigram Holdings CAD -4.76M 10.02M Mar/2026
Organon & Co USD 371M 44M Jun/2026
Pharma Mar EUR 700K 2.01M Jun/2026
Qiagen NV USD 207.66M 59.56M Jun/2026
Sartorius EUR 279.9M 600K Sep/2026
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Tilray USD 8.36M 1.82M Sep/2025
Zealand Pharma A/S -379M 348.47M Mar/2026